利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6507 条记录 (耗时 0.033 秒)

    Glycosylated immunoglobulin single variable domains
    2.
    发明授权
    Glycosylated immunoglobulin single variable domains 有权

    公开(公告)号：US11306139B2

    公开(公告)日：2022-04-19

    申请号：US15554744

    申请日：2016-03-18

    申请人： Ablynx N.V.

    发明人： Marie-Ange Buyse ,  Carlo Boutton

    IPC分类号： A61K39/00 ,  C07K16/00 ,  C12P21/08 ,  C07K16/18

    摘要： The present invention relates to glycosylated immunoglobulin variable domains, and in particular to glycosylated immunoglobulin single variable domains (the latter also being referred to herein by means of the abbreviation “ISF” or “ISVD”). The present invention relates to glycosylated immunoglobulin heavy-chain variable domains (also referred to herein as “VH domains”), and in particular to glycosylated immunoglobulin heavy-chain ISVD's. The invention in particular relates to immunoglobulin (single) variable domains that are glycosylated in such a way that the binding of said immunoglobulin (single) variable domains by so-called “pre-existing antibodies” is prevented and/or reduced (i.e. partially or essentially completely) compared to the same immunoglobulin (single) variable domain without the glycosylation of the invention being present. For example, the present invention relates to heavy-chain immunoglobulin variable domain, which contains a glycosylation site such that the amino acid residue at one of positions 10, 11, 12, 13, 14, 39, 40, 41, 42, 87, 89, 108, 110, 112, 113 or 114, and in particular one of positions 11, 13, 87, 89, 108, 110, 112, 113 or 114 (numbering according to Kabat) is or can be glycosylated.

    FcγRIIB-specific antibodies and methods of use thereof
    5.
    发明授权
    FcγRIIB-specific antibodies and methods of use thereof 有权

    公开(公告)号：US11098125B2

    公开(公告)日：2021-08-24

    申请号：US16123816

    申请日：2018-09-06

    申请人： MacroGenics, Inc.

    发明人： Leslie S. Johnson ,  Ling Huang ,  Robyn Gerena

    IPC分类号： C07K16/00 ,  C12P21/08 ,  A61K39/395 ,  C07K16/28 ,  A61K45/06 ,  C07K1/00 ,  A61K39/00

    摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than the antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

    Methods of making active antibodies from biological fluids
    6.
    发明授权
    Methods of making active antibodies from biological fluids 有权

    公开(公告)号：US11067583B2

    公开(公告)日：2021-07-20

    申请号：US16302525

    申请日：2017-05-25

    申请人： University of Maryland, Baltimore ,  The United States of America as represented by the Department of Veterans Affairs

    发明人： Mohammad Sajadi ,  Anthony DeVico ,  George Lewis

    IPC分类号： C07K16/00 ,  C07H21/04 ,  C12P21/08 ,  A61K39/395 ,  C07K1/00 ,  G01N33/68 ,  C07K1/22 ,  C07K16/10 ,  H01J49/26

    摘要： The present invention provides a method of making an antibody by identifying a circulating antibody with activity from a subject comprising i) subjecting biological fluid selected from the group consisting of blood, plasma and serum and combinations thereof from the subject to one or more rounds of affinity chromatography to purify the circulating antibody; ii) optionally further subjecting the circulating antibody to isoelectric focusing to purify the circulating antibody based on charge; iii) testing the purified circulating antibody for activity; iv) digesting the purified circulating antibody from parts i) or ii) to create an antibody fragment; v) subjecting the antibody fragment to mass spectrometry to generate a mass assignment and a deduced amino acid sequence of the antibody fragment; vi) comparing the deduced amino acid sequence with an amino acid sequence of an antibody generated from the subject's B-cells to identify an antibody sequence that matches the deduced amino acid sequence; vii) generating an antibody comprising light chain and heavy chain CDR sequences of the B-cell antibody that matches the deducted amino acid sequence of party vi); and viii) testing the antibody of part vii) for activity.

    Correctly folded etanercept in high purity and excellent yield
    9.
    发明授权
    Correctly folded etanercept in high purity and excellent yield 有权

    公开(公告)号：US10954293B2

    公开(公告)日：2021-03-23

    申请号：US16443514

    申请日：2019-06-17

    申请人： COHERUS BIOSCIENCES, INC.

    发明人： Tsutomu Arakawa ,  Douglas Farrar

    IPC分类号： A61K39/00 ,  C07K16/00 ,  C12P21/08 ,  C07K16/24 ,  C07K14/705 ,  C07K1/16 ,  A61K39/395

    摘要： A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided. The method is highly effective in separating correctly folded etanercept from incorrectly folded etanercept and aggregates in commercially attractive yields capable of affording etanercept preparations having very high purity in terms of correctly folded etanercept versus incorrectly folded etanercept. The invention is further directed to protein preparations and formulations comprising correctly folded proteins obtained using the present methods, and methods of treatment using the high purity preparations obtained from the mixed mode method.

    FcgammaRIIB-specific Fc region variant
    10.
    发明授权
    FcgammaRIIB-specific Fc region variant 有权

    公开(公告)号：US10919953B2

    公开(公告)日：2021-02-16

    申请号：US14423269

    申请日：2013-08-23

    申请人： Chugai Seiyaku Kabushiki Kaisha

    发明人： Hitoshi Katada ,  Shojiro Kadono ,  Futa Mimoto ,  Tomoyuki Igawa

    IPC分类号： C07K16/00 ,  C12P21/08 ,  A61K39/395 ,  C07K16/30 ,  C07K16/28 ,  C07K1/00 ,  A61K9/00 ,  A61K39/00

    摘要： An objective of the present invention is to provide an Fc region variant with enhanced FcγRIIb-binding activity, and/or enhanced binding selectivity to FcγRIIb compared to FcγRIIa (type R), as compared to those of a polypeptide containing an Fe region to which an amino acid alteration(s) has not been introduced; a polypeptide which includes the Fc region variant; a pharmaceutical composition containing the polypeptide; preventing therapeutic or preventive agent for immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method of enhancing FcγRIIb-binding activity and also enhancing binding selectivity to FcγRIIb compared to FcγRIIa (type R).
    It was found that a polypeptide containing an antibody Fc region variant that contains an amino acid sequence in which an amino-acid alteration at position 238 (EU numbering) is combined with other specific amino-acid alterations enhances FcγRIIb-binding activity, and/or enhances binding selectivity to FcγRIIb compared to FcγRIIa (type R).